Belgium· BE-AMP-SAM663298-00
Loqtorzi 240 mg
A toripalimab product containing toripalimab, registered in Belgium by Topalliance Biosciences Europe. The same ATC class is registered in 12 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Toripalimab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF13 (toripalimab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Toripalimab · ATC L01FF13
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Toripalimab
- Manufacturer
- Topalliance Biosciences Europe
- Country
- Belgium (BE)
- ATC code
- L01FF13
- ATC class
- Toripalimab
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Toripalimab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLOQTORZITopalliance Biosciences Europe Limited, Dublin
- FinlandLOQTORZITopalliance Biosciences Europe Limited
- IrelandLOQTORZI 240 mg concentrate for solution for infusionTopalliance Biosciences Europe Limited
- IcelandLOQTORZITopalliance Biosciences Europe Limited.
- NorwayLoqtorziTopalliance Biosciences Europe Limited
- PolandLoqtorziTMC Pharma (EU) Ltd.
- SwedenLOQTORZI 240 mg Koncentrat till infusionsvätska, lösningTopalliance Biosciences Europe Limited
- United StatesLOQTORZICoherus Oncology, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Loqtorzi
- Liechtenstein · Loqtorzi
- Norway · Loqtorzi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e8d7c7aa-2234-451a-935d-1c426ced21f9 GET /v1/drugs/e8d7c7aa-2234-451a-935d-1c426ced21f9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Loqtorzi 240 mg",
"name_fr": "Loqtorzi 240 mg",
"name_nl": "Loqtorzi 240 mg",
"amp_code": "SAM663298-00",
"strengths": [
"40.0000",
"40.0000"
],
"pack_count": 1,
"substances": [
"Toripalimab",
"Mannitol",
"Sodium Chloride",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Toripalimab",
"authorisation_numbers": [
"EU/1/24/1853/001"
]
}See everything about toripalimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.